Peyronie’s disease–outcomes of collagenase clostridium histolyticum injection: A systematic review

Austin T. Mefford, Omer Raheem, Faysal A. Yafi, Laith M. Alzweri

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Objective: To review recent literature pertaining to collagenase clostridium histolyticum (CCh)and other intralesional (IL) therapies for the treatment of Peyronie’s disease (PD).  Methods: A systematic search of literature was performed using MEDLINE and PubMed.‘Peyronie’s Disease Clostridium Histolyticum’, ‘Peyronie’s Disease Intralesional’, ‘Peyronie’sDisease Causes’, and ‘Atypical Peyronie’s Disease’ were used as query entries. Inclusion criteriarequired English text from 1980 onwards and have a full text available. Records were reviewed for study power, accuracy, and relevance to our research topic. The review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses criteria. Results: Recent literature supports the notion that CCh is the most effective IL treatment forpatients with typical and atypical PD. The capstone CCh study was the IMPRESS trial thatshowed a 34% reduction in curvature with a mean (SD)–17.0 (14.8)° reduction with IL CCh,while men in the placebo saw an average 18.2% decrease in penile bend with a mean (SD)–9.3 (13.6)° per person (P < 0.001). A shortened protocol for IL CCh treatment offered a 31.4%reduction in curvature, while decreasing cost and office visits, potentially increasing patientcompliance. Lastly, literature shows CCh is used most in atypical cases, with ~64.8% of patients being treated with CCh, probably because of the high efficacy and safetyprofile that it offers. Serious complications associated with CCh include urethralinjury, corporal rupture, and penile fracture. Conclusion: Since the approval of CCh by the United States Food and Drug Administration in2013, it has been a staple in the treatment of PD, and here we report the continuedsuperiority of this therapy. CCh is an effective, minimally invasive option in most PDpopulations; however, recent changes have made CCh unavailable for commercial use outside the United States, impacting many patients who have previously benefited.

Original languageEnglish (US)
Pages (from-to)363-369
Number of pages7
JournalArab Journal of Urology
Issue number3
StatePublished - 2021


  • Peyronie’s disease
  • Xiaflex
  • collagenase clostridium histolyticum
  • intralesional injections

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Peyronie’s disease–outcomes of collagenase clostridium histolyticum injection: A systematic review'. Together they form a unique fingerprint.

Cite this